Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it anticipates total revenue for the second quarter of 2025 to be approximately $500,000, representing YoY growth of approximately 100%. Sequentially, the Company said in expects that greater than 35% procedure growth will result in over 50% recurring revenue growth in Q2-2025 compared to Q1-2025. Perimeter said this was primarily driven by stronger current Perimeter S-Series system utilization, with significantly more interoperative OTC imaging procedures performed by existing surgeon users, and at a higher price per procedure.
Gross margin is expected to be approximately 69% for the second quarter and 61% for the six-month period ended June 30, 2025, respectively.
“We are excited that the growing adoption, both in terms of new system placements and increased current device utilization, we saw during the first three months of the year continued through the second quarter,” Perimeter’s Chief Executive Officer, Adrian Mendes, said in a statement. “To put that into perspective, six-month 2025 revenue alone is estimated to surpass revenues for all of 2024. Now, as our sales pipeline continues to build, and with the Premarket Approval application for our next-generation Perimeter B-Series under review with the FDA, we anticipate a continuation of strong growth moving forward,” he added.
Perimeter also advised that it expects initial savings from its cost control efforts will result in an approximate 30% reduction in total operating costs, starting in Q3-2025.
In addition, Perimeter announced the appointments of Abbey Goodman as Vice President, Sales, and Paolo DiPasquale as Vice President, Corporate Development.
Ms. Goodman brings over 20 years of medical device sales experience, most recently serving as Profound Medical’s Global Chief Commercial Officer. Prior to joining Profound, she progressed through a variety of senior sales leadership roles with Hologic, Novadaq Technologies, Covidien (now Medtronic), and DePuy Mitek.
Mr. DiPasquale brings a unique perspective as someone who has over 17 years of experience in the U.S. and Canadian capital markets across Equity Research, Institutional Equity, and Investment Banking at Canaccord Genuity and Stephens. Most recently, he served as Chief Strategy Officer of a gaming and marketing company, where he managed its successful capital raising strategy and go-public process on NASDAQ.
Perimeter also said that Tom Boon has recently retired as its COO, but he will continue to help guide the Company’s commercial strategy through his membership on its newly formed Industry Advisory Board (AIB). Chairing the IAB will be Diana Chan, Managing Director of BridgeGap Solutions Group. Ms. Chan played a key role in MOLLI Surgical’s journey, from building its brand presence and implementing growth strategies to its successful exit after three years of commercialization through its acquisition by Stryker Corporation. Prior to MOLLI Surgical, she held executive positions at Medtronic, Bard, and Fresenius Medical Care. Perimeter indicated that the full mandate and initial composition of its new IAB will be announced at a later date.
